Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis

Bhargavi Duvvuri,1 Lauren M. Pachman,2 Gabrielle Morgan,2 Amer M. Khojah,2 Marisa Klein-Gitelman,3 Megan L. Curran,4 Stephen Doty,5 and Christian Lood1

Objective. Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). This study was undertaken to investigate the role of neutrophils in juvenile dermatomyositis (JDM).

Methods. Electron microscopy was used to identify neutrophils in tissue. NETs were also imaged using fluorescence microscopy and quantified using a myeloperoxidase-DNA enzyme-linked immunosorbent assay (ELISA) in plasma obtained from healthy children (n = 20), disease controls (n = 29), JDM patients (n = 66), and JDM patients with history of calcifications (n = 20). Clinical data included disease activity scores and complement C4 levels. Levels of immune complexes (ICs) and calprotectin were analyzed using ELISA.

Results. Using electron microscopy, neutrophils were found to infiltrate affected muscle tissue, engulfing deposited calcium crystals. Uptake of the crystals led to neutrophil activation (P < 0.01) and subsequent phosphatidylinositol 3-kinase– and NADPH oxidase–dependent but peptidylarginine deiminase 4–independent formation of NETs, which contained mitochondrial DNA (P < 0.05), as confirmed in vivo (P < 0.001) and in vitro (P < 0.01). Peripheral NET levels were associated with calcinosis (P = 0.01), ICs (P = 0.008), and interleukin-8 levels (P = 0.004). Children with JDM had impaired NET clearance (P = 0.01), associated with autoantibody profiles including melanoma differentiation–associated protein 5 (P = 0.005), and depressed complement C4 levels (r = −0.72, P = 0.002). Furthermore, children with JDM showed evidence of neutrophil activation, with elevated levels of peroxidase activity (P = 0.02) and calprotectin (P < 0.01), which were associated with disease activity (P = 0.007), and dyslipidemia (odds ratio 4.7, P < 0.05).

Conclusion. We found novel mechanisms of both calcium crystal–mediated neutrophil activation and cell death in JDM pathophysiology. Targeting this pathway may reduce the frequency and extent of calcinosis, as well as prevent long-term development of comorbidities, including atherosclerosis.

INTRODUCTION

Juvenile dermatomyositis (JDM) is a rare vasculopathic disease with an incidence of 3.2 cases per million children each year in the United States (1). Our lack of knowledge concerning disease pathophysiology is accompanied by adverse outcomes: adults who have had JDM in childhood have evidence of premature cardiovascular damage (2). One debilitating manifestation of chronic JDM is calcinosis, the formation of calcium deposits/crystals in soft tissue, which occurs in ~30% of children with JDM (3). Of note, calcifications are most likely to be present in children who experienced a delay in the initiation of therapy and/or cutaneous inflammation; which suggests a critical association between chronic inflammation and calcifications (4).

Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs), a cell death process in which DNA is extruded together with cytoplasmic and granular content to trap and eliminate extracellular pathogens.
Although beneficial from the perspective of host–pathogen interaction, exaggerated neutrophil activation and NET formation have been linked to inflammation, cardiovascular disease, and autoimmunity, including rheumatic diseases (5–9). It was recently found that immune complexes (ICs), commonly found in autoimmune conditions, induce NET formation (5). NETs are inflammatory, and they induce interferon (IFN) production through the cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway and propagate disease in lupus-prone mice (5,10). IFNs are clearly involved in JDM (11), but the potential role of NETs has yet to be determined.

Neutrophils have received very little attention in JDM pathogenesis, likely due to the lack of their identification in JDM muscle biopsies, despite careful scrutiny (12). However, a recent proteomics study showed a "tumor necrosis factor hub" present in JDM neutrophils as compared to those in healthy children, suggesting that neutrophils are affected by the inflammatory environment (13). Further, elevated levels of the neutrophil-derived alarmin calprotectin have been reported in JDM (14). Cell-free DNA has been seen in adult DM in association with interstitial lung disease, though it is not known whether this corresponds to NETs (15,16). Furthermore, whether children with JDM have elevated levels of NETs has not been investigated.

Inasmuch as calcinosis (e.g., calcium crystals) are involved in the pathophysiology of JDM, it is noteworthy to recognize that other crystals, including cholesterol and monosodium urate monohydrate (MSU) crystals, have the capacity to induce NETosis (17,18), and foster the development of atherosclerosis and gout, respectively. Whether calcium crystals could activate neutrophils to undergo NETosis is not known.

In this report, we describe the presence of calcium crystal–mediated NETosis in children with JDM. Briefly, tissue-infiltrating neutrophils engulfed deposited crystals, triggering a phosphatidylinositol 3-kinase (PI3K)– and reactive oxygen species (ROS)–dependent but peptidylarginine deiminase 4 (PAD4)–independent cell death process leading to NETosis. Evidence of neutrophil activation and cell death was also present in the circulation, particularly in patients with calcinosis, and they were associated with markers of disease activity and dyslipidemia. Our results show several novel mechanisms through which neutrophils may contribute to JDM pathogenesis, suggesting possible new therapeutic targets, as well as biomarkers to monitor and potentially predict the development of severe disease outcomes.

**PATIENTS AND METHODS**

**Patients.** Children with JDM (n = 66), healthy children (n = 20), and age-matched disease controls (n = 29) were included in the study after age-appropriate informed consent was obtained (Institutional Review Board #2008-13457 and #2001-11715). For patient characteristics, see Supplementary Tables 1–2, available on the Arthritis & Rheumatology website at http://onlineibrary.wiley.com/doi/10.1002/art.41078/abstract. Myositis-specific autoantibodies (MSAs) were assessed at the Oklahoma Medical Research Foundation Clinical Immunology Laboratory. Calcifications were confirmed by radiography or computed tomography (19). Calcifications were removed surgically and stored at −80°C after removal of adherent connective tissue. Disease activity scores (DAS) (20) were obtained at the time of the physical examination. Neopterin levels were measured as previously described (21). Fasting lipid levels were measured by an enzymatic method using a Cobas instrument.

**Electron microscopy.** Tissue samples were preserved in 2% paraformaldehyde and 0.5% glutaraldehyde in 0.05M cacodylate buffer (pH 7.4) at 4°C for 4–18 hours. Following fixation, the tissues were treated with reduced osmium tetroxide followed by dehydration in ethyl alcohol. The Spurr’s resin (Electron Microscopy Sciences) was prepared and mixed 1:1 with propylene oxide and incubated overnight on a rotator. A change of Spurr’s resin:propylene oxide at 3:1 was made, and samples were infiltrated overnight. The final embedding was completed in pure Spurr’s resin (hard mixture) for 12–18 hours and polymerized at 60°C. Embedded samples were thin-sectioned (60–80 nm thickness) for electron microscopy using a diamond knife (Diatome) on a Reichert Ultracut E and analyzed using a Philips CM-12 transmission electron microscope at 80 kV accelerating voltage. Mineral crystal size and arrangement were studied by tilting the specimen stage through 0–20 degrees of tilt and/or by darkfield imaging (22). Individual crystals could be measured in the darkfield mode and by using the 002 diffraction line from selected-area diffraction.

**Neutrophil biomarker assays.** Peroxidase activity was analyzed as previously described (5). Levels of calprotectin (S100A8/A9) were analyzed in plasma using a commercial enzyme-linked immunosorbent assay (ELISA) kit according to the instructions of the manufacturer (R&D Systems).

**NET assays.** Human neutrophils were isolated from heparinized blood using PolymorphPrep, according to the instructions of the manufacturer (Axis-Shield). Isolated neutrophils (1 × 10⁶ cells/ml) were incubated in poly-L-lysine–coated tissue culture plates with or without the following inhibitors: diphenyleneiodonium (25 μM; Sigma), thienoyl trifluoroacetone (1 μM; Sigma), LY294002 (10 μM; Invitrogen), cytochalasin B (5 μM; Sigma), and Cl-amidine (200 μM; Calbiochem). They were incubated for 1 hour prior to addition of the stimuli, e.g., calcium crystals and phorbol myristate acetate (PMA) (20 nm). After incubation with agonist for 4 hours, NETs were detached with microrccocal nuclease (0.3 units/ml; Fisher Scientific) diluted in nuclease buffer containing 10 mM TrisHCl (pH 7.5), 10 mM MgCl₂, 2 mM CaCl₂, and 50 mM NaCl.
Detached NETs were quantified by Sytox green staining (Life Technologies). In addition, NETs were quantified using a myeloperoxidase (MPO)–DNA ELISA, as described previously (5). For fluorescence microscopy, cells were fixed with 4% paraformaldehyde, permeabilized with saponin (Alfa Aesar), and blocked with 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS), prior to staining with detection antibodies. DNA was detected using Sytox green, whereas neutrophil elastase was detected using a polyclonal rabbit antibody (ab21595; Abcam) followed by a secondary Cy5-conjugated goat anti-rabbit antibody (Jackson ImmunoResearch). The cells were visualized using an EVOS cell imaging system (Life Technologies).

**NET degradation.** To detect NET degradation (23), PMA-induced NETs were stained with Sytox green and subsequently incubated with serum (10%) in nuclease buffer for 60 minutes at 37°C. Varying concentrations of micrococcal nuclease were used as positive controls. NETs were washed between each step. NET degradation was calculated as the relative loss of NETs (Sytox green signal) in each well, using the standard curve as a reference.

**Calcium crystals.** Basic calcium phosphate (BCP) crystals were synthesized according to published protocols (24). Briefly, 15 ml 0.2M NaH₂PO₄ was mixed with 12.5 ml 0.2M CaCl₂ for 1 hour to form calcium precipitates. The precipitates were washed in water with low-speed centrifugation, followed by incubation overnight with 0.5N HCl at a final pH of 9.0 overnight. The precipitates were washed with water 4 times, followed by 70% ethanol and additional water washes. The crystals were resuspended in water and stored at 4°C until used. The surgically removed calcium crystals were fragmented using a mortar and pestle and then washed in water and ethanol, as described above, prior to use.

**ELISAs for interleukin-8 (IL-8) and ICs.** A 96-well microtiter plate (Corning Clear Polystyrene flat-bottomed, medium binding) was coated with 100 μl of capture antibody (4 μg/ml anti-human IL-8; BioLegend) diluted in PBS and incubated overnight at 4°C. After blocking (1% BSA in PBS), samples were added and incubated overnight at 4°C. For detection, plates were incubated with biotinylated detection antibody (1 μg/ml in blocking buffer), followed by the addition of horseradish peroxidase–streptavidin (BioLegend) for an additional 2 hours at room temperature. The reaction was visualized by the addition of tetramethylbenzidine. The reaction was stopped by addition of 2N sulfuric acid, and absorbance at 450 nm was measured with a plate reader. Wells were washed thoroughly 2 times in PBS–Tween between every step. Levels of ICs were assessed using a MicroVue CIC-C1q ELISA according to the instructions of the manufacturer (Quidel).

**Mitochondrial and nuclear DNA analysis.** DNA was isolated from cell culture supernatants using a Plasma/Serum Cell-Free Circulating DNA Purification Micro Kit (Thorold). The StepOnePlus Real-Time PCR System was used to perform quantitative polymerase chain reaction (PCR). Primer sequences for nuclear gene targets (ribosomal protein lateral stalk subunit P0 [RPLP0]; forward 5’-GGAATGTTGGCTTTGTTCC-3’, reverse 5’-CCCATTGCCTCCCTACTCT-3’) and mitochondrial gene targets (cytochrome c oxidase subunit 2, cytochrome c oxidase subunit II [COXII]: forward 5’-CCCCACATTAGGCTTAAAAACAGAT-3’, reverse 5’-TATCCCCCGTGTGTAAGC-3’) were reported previously (25). All components of PCR except for primers were provided in Power SYBR Green PCR Master Mix (ThermoFisher). PCR was set up in a volume of 20 μl that had a 1× final concentration of Power SYBR Green PCR Master Mix, 1 pair of primers directed against nuclear or mitochondrial genes at a final concentration of 100 nM, 5 μl of DNA, and 3 μl of PCR-grade water. Each PCR was set up using the following thermoprofile: incubation for 2 minutes at 50°C followed by a first denaturation step of 10 minutes at 95°C, and 40 cycles of 95°C for 15 seconds, 55°C (COXII) or 60°C (RPLP0) for 1 minute, and then 60°C for 1 minute. Absolute quantification of gene targets is derived from standard curves built by serial dilution of synthesized nuclear and mitochondrial genes.

**Statistical analysis.** The Mann-Whitney U test and Spearman’s correlation test were used when applicable. For comparisons of frequencies, a chi-square test was used. P values less than 0.05 were considered significant. The Bonferroni-Holm correction for multiple comparisons was applied when required.

**RESULTS**

**Neutrophil infiltration in JDM tissue.** We readily observed infiltrating neutrophils in inflamed JDM tissue, in particular adjacent to calcified muscle tissue (Figures 1A and B), which suggests chemotactic recruitment to the site of calcification. The neutrophils contained phagocytosed crystals within intracellular vesicles (Figure 1C), as did other infiltrating phagocytes, including macrophages (Figure 1D). The crystalized minerals were fairly homogeneous, 80–120 nm in size, similar to the bone components described previously (26), although the tissue-deposited crystals also formed larger aggregates of considerable size (Figures 1A and B).

**NETosis induction by calcium crystals through a ROS- and PI3K-dependent pathway.** Given that neutrophils were seen phagocytosing calcium crystals in vivo (Figures 1C and D), we investigated whether such crystals could activate neutrophils to undergo NETosis. Assessing cell surface levels of CD66b, a known neutrophil activation marker, experiments demonstrated the capacity of BCP crystals to activate
neutrophils ($P < 0.01$; Figure 1E). R848, a Toll-like receptor 7 (TLR-7)/TLR-8 agonist, was used as a positive control. To determine whether neutrophil activation proceeded to cell death, we quantified the DNA release using a fluorimetry assay ($P < 0.001$; Figure 1F), and NETs were apparent when using fluorescence microscopy (Figures 1G and H). Interestingly, only neutrophils in close proximity to the calcium crystals underwent NETosis, whereas neutrophils further away retained a nonactivated phenotype (Figures 1G and H).

NETs can be induced through several distinct signaling pathways, including generation of ROS- and PAD-mediated citrullination of histone H3. PI3K-mediated signaling has previously been shown to be essential in NET formation, acting upstream of NADPH oxidase in generating ROS (10). To investigate the signaling requirements for BCP-mediated NETosis, neutrophils were preincubated with inhibitors blocking pathways known to be involved in NET formation, including PAD2/PAD4, ROS, PI3K signaling, or actin polymerization. Calcium crystal–mediated NETosis was insensitive to PAD inhibition, though PI3K-mediated ROS production was required. This is similar to what has been described for ICs (10), in contrast to neutrophil activation via MSU crystals (found in adult gout patients), which also required PAD activity to induce NET formation (27). Furthermore, neutrophils required actin cytoskeleton activity to undergo calcium crystal–mediated NETosis (Figure 2A). It has recently been shown that NETs contain inflammatory mitochondrial DNA (5,6), which can activate type I IFNs. To determine if calcium crystals induced extrusion of mitochondrial DNA, we analyzed the content of NETs using a quantitative PCR method that assessed levels of nuclear (RPLP0) and mitochondrial (COXII) DNA. Calcium crystals induced the release of both genomic and mitochondrial DNA in a ROS- and PI3K-dependent process ($P < 0.05$; Figures 2B and C). Selective inhibition of mitochondrial ROS reduced mitochondrial DNA release but not that of nuclear DNA (Figures 2B and C). Thus, calcium crystals induced NETosis with

Figure 1. Neutrophil infiltration in the tissue of patients with juvenile dermatomyositis (JDM). A and B, Muscle tissue (from 2 children with JDM) illustrating calcium deposits (orange arrows) and infiltrating neutrophils (red arrows). Original magnification × 5,000. C and D, High-magnification views of a neutrophil engulfing individual and aggregated crystals (magnified view of a portion of A) (C) and of a macrophage with mineral crystals within vacuoles (D). Original magnification × 10,000. Red arrows indicate neutrophil lobulated nucleus, yellow arrows indicate neutrophil granules, and orange arrows indicate calcium crystals. Results are representative of >3 independent experiments. E and F, Surface expression of CD66b analyzed by flow cytometry (n = 4–6) (E) and neutrophil extracellular trap (NET) formation analyzed by fluorimetry (n = 13–15) (F). Human primary neutrophils were incubated with synthetic calcium crystals (Ca crystal), Toll-like receptor 7 (TLR-7)/TLR-8 agonist R848, or phorbol myristate acetate (PMA). Bars show the mean ± SEM. G and H, Fluorescence microscopy staining for DNA using Sytox green (G) and CD66b (H). Calcium crystals are illustrated with orange boxes and arrows. Results are representative of 3 experiments. Bars = 100 μm. * = $P < 0.05$; ** = $P < 0.01$; *** = $P < 0.001$. MFI = mean fluorescence intensity.
the release of both mitochondrial and nuclear DNA, in a ROS- and PI3K-dependent but PAD4-independent process.

**Crystals isolated from JDM patients are potent NET inducers and contain NET remnants.** Given that the BCP crystals could induce NETs in vitro, we next investigated whether tissue-deposited calcium crystals isolated from JDM patients were capable of inducing NETosis. Similar to the BCP crystals, JDM-derived crystals from surgically removed deposits induced NETosis, as was evident by the release of DNA colocalized with neutrophil elastase, as well as MPO–DNA complexes (Figures 2D and E). We then explored whether JDM crystals also induced NETosis in vivo. However, given the difficulty of processing calcified material for immunohistochemistry, we were unable to analyze the crystals by microscopy. Thus, in an attempt to answer this question, purified JDM crystals were treated with micrococcal nuclease to release crystal-bound NETs. As evident in Figure 2F, MPO–DNA complexes were released upon nuclease treatment (P < 0.01), which supports the hypothesis that JDM patients developed crystal-bound NETs in vivo.

**No evidence of NETosis in the periphery in children with JDM.** We examined whether children with JDM showed evidence of NETs in the circulation or in tissues. To investigate this, we analyzed plasma levels of MPO–DNA complexes, a well-established marker of NETosis, in children with JDM and in controls. Though levels of NETs were increased in patients with pediatric systemic lupus erythematosus (SLE) (P = 0.007), none
of the juvenile myositis groups had elevated levels of NETs (Figure 3A). Given the large variability in NET levels, we investigated whether NETs were associated with certain disease features, including calcinosis. We found that patients with calcinosis had increased levels of NETs compared to JDM patients without calcinosis \((P = 0.009)\) and compared to healthy children \((P = 0.02)\; (Figure 3B)\).

It was previously shown that SLE patients have reduced degradation of NETs due to low DNase I activity \((28)\). In the present study, there was also a marked impairment in degrading NETs in patients with pediatric SLE \((P = 0.003; \ Figure 3C)\). Similarly, using the 10th percentile of NET degradation in healthy controls as a cutoff, we found that nearly one-third of the JDM patients had an impaired capacity to degrade NETs \((P = 0.01)\), particularly patients with MDA-5 and p155/140 MSAs \((P = 0.025\) and \(P = 0.024\), respectively, by chi-square test). NET-degrading capacity correlated with complement C4 levels \((r = 0.72, P = 0.002)\; (Figure 3D)\). Surprisingly, NET degradation did not correlate with levels of NETs \((P = 0.17)\). To investigate whether NETs may contribute to inflammation in JDM, we analyzed levels of the neutrophil chemoattractant IL-8. Levels of IL-8 were elevated in all inflammatory conditions, including pediatric SLE \((P = 0.03)\), polymyositis \((P = 0.01)\), RNP+ myositis \((P = 0.02)\), and JDM \((P = 0.03)\; (Figure 3E)\). Importantly, patients with JDM who displayed NETosis had even higher levels of IL-8 \((P = 0.004; \ Figure 3F)\). These data provide evidence that a subgroup of patients with severe JDM have impaired degradation of NETs accompanied by increased circulating levels of NETs, in the presence of ongoing inflammation and calcinosis.

**Association of circulating NET levels with ICs.** Children with JDM had increased levels of ICs compared to healthy individuals \((P = 0.006; \ Figure 4A)\). Given the well-known contribution of ICs to NET formation in adult SLE, we examined whether levels of ICs correlated with NET levels in pediatric lupus. IC levels correlated strongly with NET levels in pediatric SLE \((r = 0.80, P = 0.01)\; (Figure 4B)\), suggesting that similar mechanisms may operate in pediatric and adult SLE. IC levels also correlated with NET levels in JDM patients \((r = 0.31, P = 0.02)\; (Figure 4C)\), with NET levels particularly elevated in patients with evidence of circulating ICs \((P = 0.008; \ Figure 4D)\). Patients with JDM, similar to those with pediatric SLE, had circulating ICs that appeared to contribute to heightened NET levels, as observed in a subgroup of the JDM patients.

**Figure 3.** Association of NETosis with calcinosis in JDM. A, MPO–DNA complexes (NETs) were measured in different patient groups and compared to the values in healthy children (HC). B, NET levels were analyzed in patients without calcinosis \((n = 43)\), patients with calcinosis \((n = 18)\), and healthy children. C, NET degradation was assessed in all subjects by in vitro enzymatic assay. D, Correlation between levels of complement component C4 and NET degradation \((n = 17)\) was determined using Spearman’s correlation test. E, Levels of interleukin-8 (IL-8) in all subjects were analyzed in patients without circulating NETs \((n = 44)\) and patients with circulating NETs \((n = 6)\). In A–C, E, and F, symbols represent individual samples. Bars show the median. The dotted line in A represents the 90th percentile of the relevant levels in healthy children, and in C and E, the dotted lines represent the 10th percentile of these levels. * = \(P < 0.05\); ** = \(P < 0.01\) versus healthy children or as indicated, by Mann-Whitney U test. SLE = systemic lupus erythematosus; PM = polymyositis; RNP = RNP+ polymyositis; MDA-5 = melanoma differentiation–associated protein 5 (see Figure 2 for other definitions).
Increased neutrophil activation related to disease activity in JDM patients. Given the finding that a subgroup of children with calcinosis demonstrated neutrophil cell death in peripheral blood, we explored whether these children also had evidence of neutrophil activation. To investigate this, we analyzed 2 markers of neutrophil activation in plasma: calprotectin (S100A8/A9) and peroxidase activity. In contrast to previous findings in adult SLE (5), patients with pediatric SLE did not show elevated peroxidase activity (Figure 5A). However, patients with RNP+ myositis and those with JDM showed increased peroxidase activity (P = 0.01 and P = 0.04, respectively; Figure 5A). Elevated peroxidase activity was observed in patients with high disease activity (P = 0.02; Figure 5B) and correlated with markers of inflammation, including the macrophage-derived molecule neopterin (r = 0.45, P = 0.0007; Figures 5C and D).

Elevated S100A8/A9 levels in JDM but not in pediatric SLE. It has been reported that serum S100A8/A9 levels are elevated in JDM and associated with disease activity (14). However, S100A8/A9 is released by activated platelets during the clotting process (29,30), which is why serum levels of S100A8/A9 do not reflect physiologic levels of S100A8/A9. In the current study, by using rapidly processed and frozen plasma samples to assess true levels of S100A8/A9 in patient circulation, we found that calprotectin levels were not elevated in patients with pediatric SLE (Figure 5E), even though clearly elevated levels have been demonstrated in adult SLE (31). These data suggest that children may not behave physiologically as young adults and may have a different disease pathophysiology, at least in SLE. In contrast to SLE, pediatric patients with polymyositis, RNP+ myositis, and JDM all showed elevated levels of S100A8/A9 in the circulation (P < 0.001, P = 0.006, and P < 0.01, respectively; Figure 5E). Levels of S100A8/A9 were inversely associated with Childhood Myositis Assessment Scale scores (P = 0.007; Figure 5F), suggesting that S100A8/A9 could be a marker of disease activity in JDM. In contrast to neutrophil activation markers, levels of NETs (e.g., neutrophil cell death) were not associated with disease activity in JDM patients (data not shown). Our data demonstrate that JDM patients have ongoing systemic neutrophil activation that is associated with elevated indicators of inflammation and disease activity.

Association of neutrophil activation with dyslipidemia. Neutrophil activation is instrumental in the development of endothelial damage and subsequent atherosclerosis, with elevated levels of S100A8/A9 associated with cardiovascular disease, including in SLE (29,31,32). In the present study,
consistent with prior findings (2,33), JDM patients had low levels of high-density lipoprotein (HDL), with 9 of 23 patients (39%) having dyslipidemia. Furthermore, we observed lipid droplet accumulation in endothelial cells adjacent to muscle fiber, as assessed by electron microscopy. Similar to observations in diabetes mellitus (34), levels of HDL were inversely correlated with calprotectin levels (r = −0.56, P = 0.01; Figure 6A) and decreased in children with elevated calprotectin levels (P = 0.01; Figure 6B). Finally, elevated levels of calprotectin were associated with dyslipidemia (odds ratio 4.7, P < 0.05; Figure 6D). Neutrophils and other phagocytes were involved in clearance of the mineral crystals, as demonstrated by endocytosed crystals. The presence of infiltrating neutrophils is novel in JDM; in prior studies, neutrophils were not identified in diagnostic muscle biopsies from children with JDM (12). This discrepancy may

**DISCUSSION**

Neutrophils are frontline immune cells that are recruited immediately upon insult through chemotactic signals, which forces them to leave the circulation and migrate into tissue to combat the pathogen. Similar processes occur in sterile inflammation, including rheumatic disease, wherein insults of varying kinds (e.g., IC deposition) result in recruitment of neutrophils into tissue and cause inflammation and organ damage. In this report, we describe the novel finding that neutrophils are present in affected tissue of JDM patients, particularly adjacent to calcified tissue, suggesting that calcinosis-mediated inflammation contributes to chemotactic signaling. Neutrophils and other phagocytes were involved in clearance of the mineral crystals, as demonstrated by endocytosed crystals. The presence of infiltrating neutrophils is novel in JDM; in prior studies, neutrophils were not identified in diagnostic muscle biopsies from children with JDM (12). This discrepancy may
be explained by the selection of our patients (e.g., those with calcinosis), but it may also relate to the rapid turnover of neutrophils. Consistent with our findings and similar to what has been observed in SLE and psoriasis (8,39), neutrophils succumb to cell death upon engaging calcium crystal, leaving only remnants of NETs in the tissue.

Interestingly, tissue-infiltrating neutrophils were found to engulf seemingly indigestible crystals in JDM. The interactions of neutrophils with a wide range of crystals, including cocaine crystals, uric acid crystals, mineralo-organic particles, and cholesterol crystals, have been previously described (6,17,18,40). In accordance with findings from prior investigations, we were able to demonstrate that calcium crystals, either BCP or patient-derived crystals, had the capacity to engage neutrophils to induce a process referred to as “frustrated phagocytosis” and subsequent NET formation. Briefly, as elegantly demonstrated by Branzk and colleagues, once the target is beyond the size of being engulfed, the neutrophil will become frustrated and undergo NETosis (41). Similar mechanisms also seem to apply to crystalline size (40). Though most crystals induce NET formation, the underlying signaling requirements are somewhat distinct. Consistent with many previous findings (6,17,18,40), calcium crystals induced NETs in a ROS-dependent process. In contrast, calcium pyrophosphate dehydrate crystals, which are involved in pseudogout, induced NETs in a PI3K-dependent but ROS-independent manner (42). The dependency on PAD-mediated citrullination only applies to MSU and cocaine crystals, whereas cholesterol and calcium crystals induced NETs in a citrullination-independent manner (6,17,18,40).

Further studies are needed to characterize both the common and selective signaling pathways involved in crystal-mediated NET formation. Though neutrophil activation (particularly NETosis) can be targeted pharmaceutically—which has been done successfully in other autoimmune rheumatic diseases such as lupus (5)—understanding mechanisms that act upstream of NETosis (e.g., calcinosis development) would be beneficial in identifying a more attractive drug target that could potentially lead to reduction of general inflammation and not just the neutrophil-dependent component.

Though our experimental data support the hypothesis of calcium crystal-mediated NET formation in the tissue in vivo, low levels of NETs were found in the circulation of JDM patients. These findings indicate that the cell death–inducing component (e.g., calcium crystal) is primarily found in tissue and that NET release is restricted to the site of neutrophil activation. Additionally, calcium crystals may be efficiently neutralized by serum components, reducing their NET-inducing capacity (43). What could then be the source

Figure 6. Neutrophil activation markers are associated with dyslipidemia in juvenile dermatomyositis (JDM). A, Correlation between levels of calprotectin (S100A8/A9) and fasting levels of high-density lipoprotein (HDL) in JDM patients (n = 20) was determined using Spearman’s correlation test. B, HDL levels were assessed in patients with high S100A8/A9 levels (n = 10) and patients with low S100A8/A9 levels (n = 10). C, Correlation between levels of peroxidase (Pox) activity and fasting levels of HDL in JDM patients (n = 20) was determined using Spearman’s correlation test. D, HDL levels were assessed in patients with high peroxidase activity (n = 7) and patients with low peroxidase activity (n = 13). In B and D, bars show the median. * = P < 0.05 by Mann-Whitney U test.
of peripheral NETs? It has previously been demonstrated that ICs induce NET formation in an Fcγ receptor IIA- and TLR-dependent manner in SLE (5,10). Consistent with those findings, we observed that children with pediatric SLE also had highly elevated levels of NETs, which strongly correlated with IC levels. Notably, elevated levels of ICs were also present in JDM patients and were associated with NET levels. Thus, it is likely that ICs may contribute to activation and death of neutrophils in JDM as well. Though most JDM patients did not have elevated levels of NETs in the periphery, impaired degradation, as described in our study, may still affect the persistence of NETs by promoting inflammation and damaging the vasculature (37,44). In accordance with this hypothesis, NET levels and the capacity to degrade NETs were associated with markers of inflammation, in particular IL-6 levels, in JDM patients. It has previously been demonstrated that NETs (specifically NET-derived mitochondrial DNA) were interferogenic and that they signaled through the DNA-sensing cGAS-STING pathway to induce type I IFNs (5). It is therefore likely that NETs may contribute to the prominent type I IFN signature present in JDM patients (11).

Neutrophil activation, with elevated levels of calprotectin, has been described as occurring in the sera of JDM patients and is associated with disease activity (14). However, given the activation of neutrophils and platelets during the coagulation process that results in the release of calprotectin (29,30), serum levels of calprotectin do not reflect physiologic levels of calprotectin. Our investigation is the first to assess true levels of calprotectin in patient circulation using rapidly processed plasma samples, thereby avoiding the influence of coagulation on immune cell activation. Importantly, we found that calprotectin and peroxidase levels were increased in JDM patients and were associated with markers of disease activity, implicating an important role of neutrophils in JDM pathogenesis and their potential utility as biomarkers to monitor disease progression. Furthermore, neutrophil activation (including NETosis) is detrimental in the development of endothelial damage and subsequent atherosclerosis (35–37), with elevated levels of calprotectin associated with cardiovascular disease (29,31,32), likely through facilitating extravasation and receptor for advanced glycation end products–mediated inflammation (45–47).

JDM patients experience pronounced dyslipidemia early in their disease, as demonstrated in this study, with development of atherosclerosis and increased intima-media thickness occurring during progression into adulthood (2,33). However, the role of neutrophils in the atherosclerotic process of JDM had not previously been addressed. Similar to findings in diabetes mellitus and spondyloarthritis (34,48), we observed that neutrophil activation was associated with dyslipidemia in JDM, which suggests the potential involvement of neutrophils in lipid modulation in JDM. Consistent with this interpretation is the notion that neutrophil-derived MPO promotes oxidative modification of HDL, rendering it proatherogenic (38). Further research, including longitudinal studies, is warranted in order to determine the potential contribution and prognostic value of neutrophil activation and NET formation in dyslipidemia and endothelial dysfunction in JDM.

In conclusion, we have reported on novel mechanisms of calcium crystal–mediated neutrophil activation and cell death in JDM pathogenesis. Targeting this pathway may reduce the disabling consequences of calcinosis and prevent long-term development of comorbidities, including atherosclerosis.

**AUTHOR CONTRIBUTIONS**

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Lood had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study conception and design.** Pachman, Lood.

**Acquisition of data.** Duvvuri, Morgan, Khojah, Klein-Gitelman, Curran, Doly, Lood.

**Analysis and interpretation of data.** Duvvuri, Pachman, Lood.

**REFERENCES**


